On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2.

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a late-stage study, the ...

Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated ...

Daiichi Sankyo will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific Program.

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2024, it had a debt/EBITDA ratio of 0.3 times and over JPY 700 billion in cash and ...

Blake Lively and Ryan Reynolds cracked jokes on the red carpet at the Time100 event in New York City on Thursday night as the actress is in the middle of her Justin Baldoni legal battle.

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ...

A significant factor towards achieving that level is through investment in antibody drug conjugates (ADCs), including Daiichi Sankyo’s drug Enhertu, which targets HER2-positive cancers. Since being ...

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Free Report) was the target of a significant growth in short interest in March.As of March 31st, there was short interest totalling 184,100 ...

Enhertu is the primary driver of Daiichi’s revenue. For fiscal year 2024, Enhertu forecast is ¥539.9 billion (~$3.50 billion) in global revenue, up from ¥449 billion in FY2023 (see page 11, here).

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025.Dr ...